Question

When a New Drug Application (NDA) made?

• A. Once the animal studies are done and drug is declared safe in animals.
• B. Once the animal studies are done and drug declared safe and effective in animals study.
• C. After the phase III clinical trial.
• D. After the phase IV clinical trial.

Answer 1

The Correct Option is C

The New Drug Application (NDA) is a critical step in the drug approval process in many countries, including the United States. This application is essential for getting permission from regulatory bodies to market a new pharmaceutical. Here's a step-by-step explanation regarding when an NDA is made:

1. Preclinical Studies: Initially, a potential new drug is tested in the laboratory and on animals. The goal is to determine if the drug is safe and effective in animal models. Successful completion of this step allows the researchers to proceed to human clinical trials.
2. Clinical Trials Phase I to III:
   • Phase I: This phase involves a small group of healthy volunteers to assess the drug's safety and dosage.
   • Phase II: Conducted with a larger group of people to determine the drug's efficacy and further evaluate its safety.
   • Phase III: These trials are performed on a larger group of patients to confirm the drug's effectiveness, monitor side effects, compare it to commonly used treatments, and collect all the information that will allow the drug to be used safely. This phase is crucial because it gathers the necessary data to support an NDA.
3. New Drug Application (NDA): After successful completion of Phase III trials, the data collected is used to file a New Drug Application. The NDA includes all the technical data, clinical results, and proposed labeling for the drug. This submission is made to the regulatory body (such as the FDA in the United States) to review the safety and efficacy of the drug for marketing approval.
4. Phase IV Trials: These are post-marketing studies that provide additional information, including the drug's risks, benefits, and optimal use. However, they occur after the NDA has been approved and the drug has entered the market.

Given these steps, the correct answer to when an NDA is submitted is "After the phase III clinical trial." This is because, up to this point, enough data has been collected to demonstrate the drug's safety and effectiveness, justifying regulatory review for market approval.